Nguyen Minh T, Tsukikawa Mai, Lomazow Whitney, Lee Michele
Department of Ophthalmology, University of Washington, Seattle, Washington, USA.
Case Rep Ophthalmol. 2022 Aug 19;13(2):638-642. doi: 10.1159/000525738. eCollection 2022 May-Aug.
This report highlights a case of irreversible bilateral cicatricial keratoconjunctivitis related to dupilumab therapy for the treatment of severe atopic dermatitis (AD). After 38 years of AD, the patient began dupilumab therapy and achieved disease control. Two years into treatment, his ophthalmic examination was significant for bilateral cicatricial keratoconjunctivitis with severe foreshortening of the inferior conjunctival fornices, symblepharon, and ankyloblepharon, which persisted even after topical steroid eye drops and discontinuation of dupilumab. Treating dermatologists should be aware of this potential irreversible adverse effect, and we recommend that patients are monitored for ocular complications while on dupilumab therapy.
本报告重点介绍了一例与度普利尤单抗治疗重度特应性皮炎（AD）相关的不可逆双侧瘢痕性角结膜炎病例。患AD 38年后，患者开始接受度普利尤单抗治疗并实现了疾病控制。治疗两年后，其眼科检查显示双侧瘢痕性角结膜炎，伴有下结膜穹窿严重缩短、睑球粘连和睑缘粘连，即使使用局部类固醇眼药水并停用度普利尤单抗后仍持续存在。皮肤科治疗医生应意识到这种潜在的不可逆不良反应，我们建议在患者接受度普利尤单抗治疗期间监测眼部并发症。
